“…Studies by Sakaguchi and Machiyama using atezolizumab and durvalumab, respectively, in extensive-disease small cell lung cancer (ED-SCLC) have reported the effectiveness of ICI in controlling the primary lesion and improving neurological symptoms. Management of neurological symptoms in these reports involved the use of IVIG, 3,4-diaminopyridine, pyridostigmine, and other medications [ 10 , 11 ]. In cases with severe neurological symptoms, these medications should be considered before starting chemotherapy.…”